• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Multi ‑faceted roles of cathepsins in ischemia reperfusion injury (Review)
Mol Med Rep. 2022 Dec;26(6):368. doi: 10.3892/mmr.2022.12885. Epub 2022 Oct 27.ABSTRACTCathepsins are one of the most abundant proteases within the lysosomes with diverse physiological effects ranging from immune responses, cell death and intracellular protein degradation. Cathepsins are involved in extracellular and systemic functions such as systemic inflammation and extracellular matrix degradation. Ischemia reperfusion (IR) injury is responsible for numerous diseases including myocardial infarction, acute kidney injury, stroke and acute graft failure after transplant surgery. Inflammation plays a major role in the repe...
Source: Molecular Medicine Reports - October 27, 2022 Category: Molecular Biology Authors: Jaime Huertas H Thomas Lee Source Type: research

Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease
CONCLUSIONS: HIF stabiliser management of anaemia had uncertain effects on CV death, fatigue, death (any cause), CV outcomes, and kidney failure compared to placebo or ESAs. Compared to placebo or ESAs, HIF stabiliser management of anaemia probably decreased the proportion of patients requiring blood transfusions, and probably increased the proportion of patients reaching the target Hb when compared to placebo.PMID:36005278 | DOI:10.1002/14651858.CD013751.pub2
Source: Cochrane Database of Systematic Reviews - August 25, 2022 Category: General Medicine Authors: Patrizia Natale Suetonia C Palmer Allison Jaure Elisabeth M Hodson Marinella Ruospo Tess E Cooper Deirdre Hahn Valeria M Saglimbene Jonathan C Craig Giovanni Fm Strippoli Source Type: research

A population cohort analysis of English transplant centers indicates major adverse cardiovascular events after kidney transplantation.
Major adverse cardiovascular event (MACE) rates immediately after kidney transplantation remain uncertain due to heterogeneous reporting in the literature. To clarify this, we retrospectively studied every eligible kidney transplant procedure performed in England between April 1, 2002 and March 31. 2018 with follow-up through August 31, 2019. The primary outcome of interest was MACE broadly defined as any hospital admission with myocardial infarction, stroke, unstable angina, heart failure, any coronary revascularisation procedure and/or any cardiovascular death.
Source: Kidney International - June 15, 2022 Category: Urology & Nephrology Authors: Benjamin Anderson, Muhammad Qasim, Felicity Evison, Suzy Gallier, Jonathan N. Townend, Charles J. Ferro, Adnan Sharif Tags: clinical investigation Source Type: research

CZecking heart failure in patients with advanced chronic kidney disease (Czech HF-CKD): Study protocol
DISCUSSION: This trial will differ from others by: (1) detailed repeated hemodynamic assessment including arteriovenous access flow and (2) by careful assessment of adequate hydration to avoid confusion between HF and water overload.PMID:35676802 | DOI:10.1177/11297298221099843
Source: The Journal of Vascular Access - June 9, 2022 Category: Surgery Authors: Jan Malik Anna Valerianova Satu Sinikka Pesickova Zdenka Hruskova Vladimira Bednarova Pavel Michalek Vladimir Polakovic Vladimir Tesar Source Type: research

Defective KIM-1 phagocytosis does not predispose to acute graft dysfunction after kidney transplantation in humans
Introduction: Ischemia reperfusion injury (IRI) is common to several pathologic conditions, including myocardial infarction, stroke, acute kidney injury, and delayed graft function after kidney transplantation1. Clearance of apoptotic and necrotic cells by resident immune or epithelial cellsS1,S2 prevents release of harmful intracellular pro-inflammatory mediators, and is thought to represent an important mechanism to dampen secondary tissue damage and promote repair after acute injury including IRI2, 3, S3, S4.
Source: Kidney International - May 27, 2022 Category: Urology & Nephrology Authors: Rita S. Suri, Ji Yun Lee, Matthew R. Ban, Bradly Shrum, Elena Tutunea-Fatan, Ola Z. Ismail, Steven Leckie, Adam McIntyre, Qingyong Xu, Seung Ho Lee, Sonali de Chickera, Robert A. Hegele, Lakshman Gunaratnam Tags: research letter Source Type: research

Kidney transplantation waiting times and risk of cardiovascular events and mortality: a retrospective observational cohort study in Taiwan
Conclusions Our results demonstrate that early KT is associated with superior long-term cardiovascular outcomes compared with late KT in selected patients with ESRD receiving uncomplicated KT, suggesting that an early KT could be a better treatment option for patients with ESRD who are eligible for transplantation.
Source: BMJ Open - May 24, 2022 Category: General Medicine Authors: Chen, H.-H., Chern, Y.-B., Hsu, C.-Y., Tang, P.-L., Lai, C.-C. Tags: Open access, Epidemiology Source Type: research

New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition (DPI) with XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD)
RARITAN, N.J., May 23, 2022 – Findings from the XARELTO® (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and the XARELTO® in Combination with Acetylsalicylic Acid (XATOA) registry have been published in the European Society of Cardiology’s (ESC) European Heart Journal, Cardiovascular Pharmacotherapy. Additionally, the XATOA registry was presented at the American Congress of Cardiology’s 71st Annual Scientific Session (ACC.22). These studies provide further evidence supporting the role of dual pathway inhibition (DPI) with the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 100 mg...
Source: Johnson and Johnson - May 23, 2022 Category: Pharmaceuticals Source Type: news

Data from New VOYAGER PAD Analyses at ACC.22 Reinforce Benefit of XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Peripheral Artery Disease (PAD) and Various Co-Morbid Conditions
RARITAN, N.J., April 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from new analyses from the Phase 3 VOYAGER PAD clinical trial reinforcing the benefit of the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) in reducing severe vascular events in patients with PAD after lower-extremity revascularization (LER), a procedure that restores blood flow to the legs. Data from the two analyses demonstrate the role that the XARELTO® vascular dose plays in PAD patients with and without chronic kidney disease (CKD) and in PAD patients with and ...
Source: Johnson and Johnson - April 1, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Pages: 1  2  3  4  5  6  7  8  9  10